Updated Jul 16, 2026
Myers Scott Dunseth has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $41K.
Scott Dunseth Myers is a corporate executive known for his role as a Director at Dynavax Technologies Corp and Zentalis Pharmaceuticals, Inc. He has been involved in SEC filings related to these companies, indicating his participation in corporate governance.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | ZNTL | Zentalis Pharmaceuticals, Inc. | A — Grant or award | 57.1K | $0.00 | |
| 2026-02-10 | DVAX | DYNAVAX TECHNOLOGIES CORP | D — Derivative transaction | 31.2K | — | |
| 2026-02-10 | DVAX | DYNAVAX TECHNOLOGIES CORP | J — Other acquisition / disposition | 3.8K | — | |
| 2025-08-22 | DVAX | DYNAVAX TECHNOLOGIES CORP | P — Open-market purchase | 3.8K | $10.82 | $41K |
| 2025-06-11 | DVAX | DYNAVAX TECHNOLOGIES CORP | A — Grant or award | 5.8K | $0.00 | |
| 2024-11-13 | ZNTL | Zentalis Pharmaceuticals, Inc. | A — Grant or award | 260.2K | $0.00 |
Scott Dunseth Myers is a corporate executive known for his role as a Director at Dynavax Technologies Corp and Zentalis Pharmaceuticals, Inc. He has been involved in SEC filings related to these companies, indicating his participation in corporate governance.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($41K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Myers Scott Dunseth profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.